10
Sep
2026
Novartis’ Rough Week, AstraZeneca’s Better Week, & GV Life Sciences Leader Moves On
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2026
Drugs That Go Where None Could Before: Mathai Mammen on The Long Run
Mathai Mammen is today’s guest on The Long Run. Mathai is the CEO of Cambridge, Mass.-based Parabilis Medicines. The company has a platform for making drugs that hit elusive biological targets known as drivers of disease. Parabilis attacks them with alpha-helical peptide drug candidates that can get inside cells and bind with relatively flat and smooth surfaces of proteins. It... Read More
3
Sep
2026
Alumis & BioNTech Stumble, Lilly Buys Merida, & Takeda’s Latest FDA Approval
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Sep
2026
IYKYK: Leave the Vortex, Take the Influence
It’s not just your kids who aspire to become influencers. Attracting attention –- often through provocative content delivered through social media at high volume –- can seem increasingly like a business imperative, as the a16z co-founders have described (here, here) and, in the case of Andreessen, unhesitatingly embraced. The Attention Imperative But they’re not alone; many physicians, researchers, and policy... Read More
27
Aug
2026
RevMed’s Watershed, Roivant Goes Commercial, & Roche’s Blood Test for Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Aug
2026
A Vaccine for Epstein-Barr Virus: Gary Nabel on The Long Run
Gary Nabel is today’s guest on The Long Run. Gary is the CEO of Weston, Mass.-based ModeX Therapeutics. The company has a platform for making multi-specific biologics into vaccines and cancer treatments. ModeX was founded in 2020, building on work that started at Sanofi when Nabel was the chief scientific officer there. The initial application of this technology, currently in... Read More
20
Aug
2026
Moderna’s Home Run, Amylyx Bounces Back, & Enveda Advances Workout-in-a-Pill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Aug
2026
9 Young Scientists to Watch: the Timmerman Traverse Fellows at Damon Runyon
Our community’s steadfast support of science is more important than ever given the tenuous state of federal research funding. Teams of biotech executives and investors have raised $3.9 million for high-risk/high-reward cancer research since 2024 as part of the Timmerman Traverse for Damon Runyon Cancer Research Foundation. The Traverse has created fun outdoor experiences and lasting friendships. We’ve hit the... Read More
17
Aug
2026
Harell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery
The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something useful – predicting protein structures in this case. Those scientists never got a nickel. This is just one of many... Read More
16
Aug
2026
The Narrative Machine: What AI Really Adds to Personal Health Data
For years, the Quantified Self movement had a stubborn problem: our devices became increasingly good at generating data but remained remarkably poor at telling us what any of it meant. Generative AI now dangles a tantalizing possibility: that it can tease genuinely useful personal insights from all those measurements and hand them back to us in a form we can... Read More
15
Aug
2026
The Other Side of Bayes: Rethinking False Positives in Health Screening
Imagine screening 10,000 apparently healthy people for a disease that affects one person in a thousand. Let’s further assume the test is fairly good: 99% sensitive and 99% specific. (In case it’s been a while, this means the test detects 99% of true cases and correctly exonerates 99% of people without disease.) Ten of those 10,000 people will actually have... Read More
14
Aug
2026
AI in Drug R&D: At Last, the End of the Beginning
With the emergence of AI as an increasingly dominant force in industry (and society), much of the early discussion around AI in biopharma has tended to treat it largely as an abstraction. Advocates and investors insist AI is a transformative superhuman technology poised to domesticate R&D, while cynics, including many grizzled drug hunters, tend to assume it’s just the latest... Read More
13
Aug
2026
Jazz Scoops Up Epilepsy Drug, Boulevard Aims for Immune Reset, & AbCellera Matures
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Aug
2026
Genetic Medicines For Kidney Diseases: Jason Coloma on The Long Run
Jason Coloma is today’s guest on The Long Run. Jason is the CEO of South San Francisco-based Maze Therapeutics. The company is developing small molecule drugs to halt or potentially reverse kidney diseases. The drug discovery work at Maze is grounded in human genetics, looking at large pools of data to see how variants of one kind or another can... Read More
6
Aug
2026
Takeda Wins First-in-Class Orexin OK, Lilly’s Obesity Money Gusher, & Three New IPOs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Aug
2026
LifeMine, In Verdine’s Big Year, Raises $263M For Safer Drug for Organ Transplants
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Jul
2026
J&J Buys In Vivo CAR-T, Sarepta’s New Boss, & Three IPOs in the Queue
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jul
2026
Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run
Lyn Baranowski is today’s guest on The Long Run. Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases. Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more... Read More
23
Jul
2026
Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2026
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.